ADAMTS13 and microvascular thrombosis

References

• Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc. NY Pathol. Soc.24, 21–24 (1924).
   Google Scholar
• Gasser C, Gautier E, Steck A, Siebenmann RE, and Oechslin R. Hamolytisch-uramische sydrome: bilaterale Nierenrindennekrosen bei akutenerworbenen hamolytischen anamien. Schweiz. Med. Wochenshr.85, 905–909 (1955).
   PubMedGoogle Scholar
• Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet1, 619–620 (1983).
   PubMed Web of Science ®Google Scholar
• Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; Chronic thrombocytopenia due to its deficiency. Blood16, 943–957 (1960).
   PubMed Web of Science ®Google Scholar
• Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N. Engl J. Med.298, 1350–1352 (1978).
   PubMed Web of Science ®Google Scholar
• Goodship TH. Atypical HUS and complement dysregulation. J. Am. Soc. Nephrol.17, 1775–1776 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int.70, 16–23 (2006).
   PubMedGoogle Scholar
• Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Ann. Rev. Med.57, 419–436 (2006).
   PubMed Web of Science ®Google Scholar
• Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature413, 488–494 (2001).
   PubMed Web of Science ®Google Scholar
• Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem.276, 41059–41063 (2001).
   PubMed Web of Science ®Google Scholar
• Soejima K, Mimura N, Hirashima M et al. A novel human metalloprotease synthesized in the liver and secreted into the Blood: possibly, the von Willebrand factor-cleaving protease? J. Biochem. (Tokyo)130, 475–480 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou W, Inada M, Lee TP et al. ADAMTS13 is expressed in hepatic stellate cells. Lab. Invest.85, 780–788 (2005).
   PubMedGoogle Scholar
• Uemura M, Tatsumi K, Matsumoto M et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood106, 922–924 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Murata M, Matsubara Y et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem. Biophys. Res. Commun.313, 212–216 (2004).
   PubMedGoogle Scholar
• Liu L, Choi H, Bernardo A et al. Platelet-derived vWF-cleaving metalloprotease ADAMTS-13. J. Thromb. Haemost.3, 2536–2544 (2005).
   PubMedGoogle Scholar
• Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J. Thromb. Haemost.4, 1396–1404 (2006).
   PubMedGoogle Scholar
• Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J. Biol. Chem.280, 39934–39941 (2005).
   PubMed Web of Science ®Google Scholar
• Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J. Biol. Chem.280, 29428–29434 (2005).
   PubMedGoogle Scholar
• Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J. Biol. Chem.278, 30136–30141 (2003).
   PubMed Web of Science ®Google Scholar
• Soejima K, Matsumoto M, Kokame K et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood102, 3232–3237 (2003).
   PubMedGoogle Scholar
• Luken BM, Turenhout EA, Hulstein JJ, van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost.93, 267–274 (2005).
   PubMed Web of Science ®Google Scholar
• Klaus C, Plaimauer B, Studt JD et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood103, 4514–4519 (2004).
   PubMed Web of Science ®Google Scholar
• Chauhan AK, Motto DG, Lamb CB et al. Systemic antithrombotic effects of ADAMTS13. J. Exp. Med.203, 767–776 (2006).
   Google Scholar
• Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood83, 2171–2179 (1994).
   PubMed Web of Science ®Google Scholar
• Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood87, 4235–4244 (1996).
   PubMed Web of Science ®Google Scholar
• Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood88, 2939–2950 (1996).
   PubMed Web of Science ®Google Scholar
• Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J. Mol. Med.80, 639–647 (2002).
   PubMed Web of Science ®Google Scholar
• Donadelli R, Orje JN, Capoferri C, Remuzzi G, Ruggeri ZM. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. Blood107, 1943–1950 (2006).
   PubMedGoogle Scholar
• Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin. Thromb. Hemost.29, 479–488 (2003).
   PubMedGoogle Scholar
• Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood105, 1085–1093 (2005).
   PubMed Web of Science ®Google Scholar
• Dong JF, Moake JL, Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood100, 4033–4039 (2002).
   PubMed Web of Science ®Google Scholar
• Motto DG, Chauhan AK, Zhu G et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J. Clin. Invest.115, 2752–2761 (2005).
   PubMedGoogle Scholar
• Bonnefoy A, Daenens K, Feys HB et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial vWF from cleavage by ADAMTS13. Blood107, 955–964 (2006).
   PubMed Web of Science ®Google Scholar
• Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood91, 2839–2846 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med.339, 1585–1594 (1998).
   PubMedGoogle Scholar
• Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med.339, 1578–1584 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai HM, Raoufi M, Zhou W et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost.95, 886–892 (2006).
   PubMedGoogle Scholar
• Kokame K, Matsumoto M, Soejima K et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc. Natl Acad. Sci. USA99, 11902–11907 (2002).
   PubMedGoogle Scholar
• Schneppenheim R, Budde U, Oyen F et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood101(5), 1845–1850 (2003).
   PubMed Web of Science ®Google Scholar
• Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal vWF cleaving protease activity. Blood101, 4449–4451 (2003).
   PubMedGoogle Scholar
• Antoine G, Zimmermann K, Plaimauer B et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br. J. Haematol.120, 821–824 (2003).
   PubMed Web of Science ®Google Scholar
• Assink K, Schiphorst R, Allford S et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int.63, 1995–1999 (2003).
   PubMedGoogle Scholar
• Bestetti G, Stellari A, Lattuada A et al. ADAMTS13 genotype and vWF protease activity in an Italian family with TTP. Thromb. Haemost.90, 955–956 (2003).
   PubMedGoogle Scholar
• Veyradier A, Lavergne JM, Ribba AS et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J. Thromb. Haemost.2, 424–429 (2004).
   PubMed Web of Science ®Google Scholar
• Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood103, 627–629 (2004).
   PubMedGoogle Scholar
• Matsumoto M, Kokame K, Soejima K et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw–Schulman syndrome. Blood103, 1305–1310 (2004).
   PubMed Web of Science ®Google Scholar
• Uchida T, Wada H, Mizutani M et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood104, 2081–2083 (2004).
   PubMedGoogle Scholar
• Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am. J. Hematol.77, 387–390 (2004).
   PubMedGoogle Scholar
• Plaimauer B, Fuhrmann J, Mohr G et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood107, 118–125 (2006).
   PubMedGoogle Scholar
• Shibagaki Y, Matsumoto M, Kokame K et al. Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol. Dial. Transplant.21, 1289–1292 (2006).
   Google Scholar
• Tsai HM, Chandler WL, Sarode R et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr. Res.49, 653–659 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien JR, Tsai HM, Etherington MD. Defective von Willebrand factor activity detected by the filterometer in three clinical conditions. Platelets11, 388–394 (2000).
   PubMedGoogle Scholar
• Veyradier A, Nishikubo T, Humbert M et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation102, 2460–2462 (2000).
   PubMed Web of Science ®Google Scholar
• Vincentelli A, Susen S, Le TT et al. Acquired von Willebrand syndrome in aortic stenosis. N. Engl. J. Med.349, 343–349 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood89, 1954–1962 (1997).
   PubMedGoogle Scholar
• O’Brien LA, Sutherland JJ, Hegadorn C et al. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers. J. Thromb. Haemost.2, 1135–1142 (2004).
   PubMedGoogle Scholar
• Hassenpflug WA, Budde U, Obser T et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood107, 2339–2345 (2006).
   PubMedGoogle Scholar
• Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic pupura, with special reference to factor VIII related antigen. Pediatr. Res.49, 653–659 (2001).
   PubMedGoogle Scholar
• Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States – analysis of national mortality data, 1968–1991. Am. J. Hematol.50, 84–90 (1995).
   PubMed Web of Science ®Google Scholar
• Miller DP, Kaye JA, Shea K et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology15, 208–215 (2004).
   PubMed Web of Science ®Google Scholar
• Hymes KB, Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy. Semin. Hematol.34, 117–125 (1997).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann. Intern. Med.128, 541–544 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann. Intern. Med.132, 794–799 (2000).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med.342, 1773–1777 (2000).
   PubMed Web of Science ®Google Scholar
• Zakarija A, Bandarenko N, Pandey DK et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke35, 533–537 (2004).
   PubMed Web of Science ®Google Scholar
• Bukowski R. M. Thrombotic thrombocytopenic purpura. A review. Prog. Hemost. Thromb.6, 287–337 (1982).
   PubMedGoogle Scholar
• Kennedy SS, Zacharski LR, Beck JR. Thrombotic thrombocytopenic purpura: analysis of 48 unselected cases. Semin. Thromb. Hemost.6, 341–349 (1980).
   PubMed Web of Science ®Google Scholar
• Coppo P, Bengoufa D, Veyradier A et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore)83, 233–244 (2004).
   PubMedGoogle Scholar
• Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur. J. Haematol.70, 183–185 (2003).
   PubMed Web of Science ®Google Scholar
• Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J. Clin. Apheresis.19, 86–89 (2004).
   PubMedGoogle Scholar
• Schiff DE, Roberts WD, Willert J, Tsai HM. Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency. J. Pediatr. Hematol. Oncol.26, 535–538 (2004).
   PubMedGoogle Scholar
• Noris M, Bucchioni S, Galbusera M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J. Am. Soc. Nephrol.16, 1177–1183 (2005).
   PubMed Web of Science ®Google Scholar
• Jubinsky PT, Moraille R, Tsai HM. Thrombotic thrombocytopenic purpura in a newborn. J. Perinatol.23, 85–87 (2003).
   PubMedGoogle Scholar
• Tripodi A, Chantarangkul V, Bohm M et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J. Thromb. Haemost.2, 1601–1609 (2004).
   PubMedGoogle Scholar
• Rieger M, Ferrari S, Kremer Hovinga JA et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb. Haemost.95, 212–220 (2006).
   PubMedGoogle Scholar
• Shelat SG, Smith P, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J. Thromb. Haemost.4, 1707–1717 (2006).
   PubMedGoogle Scholar
• Rieger M, Mannucci PM, Hovinga JA et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood106, 1262–1267 (2005).
   PubMed Web of Science ®Google Scholar
• Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol. J.2, 292–299 (2001).
   PubMedGoogle Scholar
• Schneppenheim R, Kremer Hovinga JA, Becker T et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb. Haemost.96, 3–6 (2006).
   PubMed Web of Science ®Google Scholar
• Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br. J. Haematol.124, 787–795 (2004).
   PubMed Web of Science ®Google Scholar
• George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J. Clin. Apher.21, 49–56 (2006).
   PubMed Web of Science ®Google Scholar
• Banno F, Kokame K, Okuda T et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood107, 3161–3166 (2006).
   PubMedGoogle Scholar